QUOTED. 20 May 2020. Scott Whitaker.
The decision to again postpone Medicare coverage for FDA-cleared breakthrough devices rule came as a disappointment to industry groups such as AdvaMed, though CEO Scott Whitaker continues to hope that the regulation will be put in place in December.
“While it’s certainly disappointing that a Medicare policy to help suffering seniors was delayed, we look forward to continuing to make the case that breakthrough medical technologies deemed safe and effective by the FDA should be quickly covered by Medicare. We remain hopeful that CMS will work with us to achieve this important goal of improving Medicare beneficiaries’ access to lifesaving treatments.” – Scott Whitaker, CEO, AdvaMed
Click here for a free trial of Medtech Insight